文献速递胸部腹部技术与安全CT

免疫检查点抑制剂治疗小细胞肺癌患者体部CT上的免疫相关不良事件

Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
PubMed 文献 · Eur J Radiol · 2020-09-10

研究纳入53例复发/难治性小细胞肺癌患者,接受PD-1/PD-L1抑制剂单用或联合CTLA-4抑制治疗,体部CT检出36%患者存在影像学可见的免疫相关不良事件,中位发生时间7.1周,肺炎和结肠炎最常见各17%,既往胸部放疗与肺炎或甲状腺炎显著相关。

要点

  • 免疫检查点抑制剂治疗小细胞肺癌患者中36%在体部CT出现影像学可见的免疫相关不良事件,中位发生时间7.1周。
  • 肺炎和结肠炎最常见,各占17%;肺炎常见模式为急性间质性肺炎/急性呼吸窘迫综合征模式和隐源性机化性肺炎模式。
  • 既往胸部放疗与肺炎或甲状腺炎的发生显著相关(p=0.0004),高龄和既往任何器官放疗与总体免疫相关不良事件相关。

关键影像表现/征象

  • 结肠炎9例(17%),其中7例表现为全结肠炎,2例表现为与憩室病相关的节段性结肠炎。
  • 肺炎9例(17%),常见影像模式为急性间质性肺炎/急性呼吸窘迫综合征模式4例和隐源性机化性肺炎模式3例。
  • 其他免疫相关不良事件包括甲状腺炎3例、小肠炎2例、肝炎1例、胰腺炎1例。

诊断标准与关键数值

  • 影像学可见的免疫相关不良事件总体发生率为36%(19/53),中位发生时间为治疗开始后7.1周。
  • 高龄(p=0.03)和既往任何器官放疗(p=0.03)与总体免疫相关不良事件相关。
  • 既往胸部放疗与肺炎或甲状腺炎显著相关(p=0.0004)。

临床应用与阅片要点

  • 在免疫检查点抑制剂治疗的小细胞肺癌患者体部CT随访中,应关注甲状腺炎、肺炎、肝炎、胰腺炎、小肠炎和结肠炎的影像表现。
  • 肺炎的影像模式包括急性间质性肺炎/急性呼吸窘迫综合征模式和隐源性机化性肺炎模式,结肠炎可表现为全结肠炎或与憩室病相关的节段性结肠炎。
  • 既往胸部放疗患者发生肺炎和甲状腺炎的风险更高,阅片时需结合放疗史。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Investigate the incidence and imaging characteristics of radiologically-evident immune-related adverse events (irAEs) on body CT in patients with small-cell lung cancer (SCLC) treated with immune-checkpoint inhibitors.

METHODS: The study included 53 patients with relapsed/refractory SCLC (27 men, 26 women) treated with PD-1/PD-L1 inhibitors alone or in combination with CTLA-4 inhibition, who had baseline and at least one follow-up body CT during therapy. Body CT scans were reviewed to detect and characterize organ-specific irAEs including thyroiditis, pneumonitis, hepatitis, pancreatitis, enteritis, and colitis.

RESULTS: Nineteen patients (36 %) developed radiologically-evident irAEs. The median time from therapy initiation to irAE onset was 7.1 weeks. Pneumonitis and colitis were most common, noted in 9 patients (17 %) each. Seven colitis cases demonstrated pancolitis, and two cases showed segmental colitis associated with diverticulosis. The common radiographic patterns of pneumonitis were acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) pattern (n = 4) and cryptogenic organizing pneumonia (COP) pattern (n = 3). Other irAEs included thyroiditis (n = 3), enteritis (n = 2), hepatitis (n = 1), and pancreatitis (n = 1). Older age (p = 0.03) and prior radiotherapy to any organ (p = 0.03) was associated with overall irAEs. Prior chest radiotherapy was significantly associated with pneumonitis or thyroiditis (p = 0.0004).

CONCLUSION: Radiologically-evident irAEs were noted on body CT in 36 % of patients with SCLC treated with immune-checkpoint inhibitors. Colitis and pneumonitis were most common. Prior chest radiotherapy was a predictor of the development of both pneumonitis and thyroiditis. Awareness of risk factors and CT findings of irAEs is important for early detection and accurate diagnosis of potentially serious immunotherapy toxicities.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Park H, Hatabu H, Ricciuti B, et al. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020. PMID: 32949913. doi:10.1016/j.ejrad.2020.109275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。